2022
Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, Justice AC, Napravnik S, Edwards JK, Browne LE, Agil DM, Silverberg MJ, Skarbinski J, Leyden WA, Stewart C, Hogan BC, Gebo KA, Marconi VC, Williams CF, Althoff KN. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open 2022, 5: e2236397. PMID: 36227594, PMCID: PMC9561947, DOI: 10.1001/jamanetworkopen.2022.36397.Peer-Reviewed Original ResearchConceptsBreakthrough COVID-19Breakthrough infectionsHIV statusCohort studySevere illnessMAIN OUTCOMEBreakthrough SARS-CoV-2 infectionCOVID-19 vaccine typesLow CD4 cell countsSARS-CoV-2 infectionCOVID-19Severe immune suppressionCD4 cell countProportion of patientsCells/μLPrevious COVID-19Additional vaccine dosesProportional hazards modelDiscrete-time proportional hazards modelsRisk reduction recommendationsVaccine guidelinesCD4 cellsCumulative incidenceHazard ratioClinical factors
2021
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, Skanderson M, Brittain E, King JT, Ho YL, Eden S, Kundu S, Lann MF, Greevy RA, Ho PM, Heidenreich PA, Jacobson DA, Douglas IJ, Tate JP, Evans SJW, Atkins D, Justice AC, Freiberg MS. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. The BMJ 2021, 372: n311. PMID: 33574135, PMCID: PMC7876672, DOI: 10.1136/bmj.n311.Peer-Reviewed Original ResearchConceptsProphylactic anticoagulationDay mortalityEarly initiationTherapeutic anticoagulationCohort studyInpatient mortalityHospital admissionAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCoronavirus disease 2019 (COVID-19) mortalitySyndrome coronavirus 2 infectionCOVID-19History of anticoagulationSerious bleeding eventsCoronavirus 2 infectionHours of admissionObservational cohort studyRisk of deathCoronavirus disease 2019Real-world evidenceBleeding eventsSubcutaneous heparinHospital stayNationwide cohortCumulative incidence
2017
Risk of End‐Stage Renal Disease in HIV‐Positive Potential Live Kidney Donors
Muzaale AD, Althoff KN, Sperati CJ, Abraham AG, Kucirka LM, Massie AB, Kitahata MM, Horberg MA, Justice AC, Fischer MJ, Silverberg MJ, Butt AA, Boswell SL, Rachlis AR, Mayor AM, Gill MJ, Eron JJ, Napravnik S, Drozd DR, Martin JN, Bosch RJ, Durand CM, Locke JE, Moore RD, Lucas GM, Segev DL. Risk of End‐Stage Renal Disease in HIV‐Positive Potential Live Kidney Donors. American Journal Of Transplantation 2017, 17: 1823-1832. PMID: 28497525, PMCID: PMC5489376, DOI: 10.1111/ajt.14235.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase-Control StudiesFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHIV InfectionsHIV SeropositivityHIV-1HumansIncidenceKidney Failure, ChronicKidney Function TestsKidney TransplantationLiving DonorsMaleMiddle AgedNephrectomyNorth AmericaPrognosisRisk FactorsViral LoadConceptsEnd-stage renal diseaseIncidence of ESRDHIV-positive individualsLive kidney donorsKidney donorsRenal diseaseMultivariable Cox proportional hazards regressionCox proportional hazards regressionPotential live kidney donorsHIV-negative peersHIV-negative participantsHIV-positive participantsProportional hazards regressionCopies/mLKidney donor candidatesCumulative incidence estimatesCohort CollaborationCumulative incidenceHIV infectionViral loadHazards regressionNational HealthPositive individualsIncidence estimatesHealth characteristics
2016
First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013
Wong C, Gange SJ, Buchacz K, Moore RD, Justice AC, Horberg MA, Gill MJ, Koethe JR, Rebeiro PF, Silverberg MJ, Palella FJ, Patel P, Kitahata MM, Crane HM, Abraham AG, Samji H, Napravnik S, Ahmed T, Thorne JE, Bosch RJ, Mayor AM, Althoff KN, Research and Design F. First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013. Clinical Infectious Diseases 2016, 64: 459-467. PMID: 28172581, PMCID: PMC5850614, DOI: 10.1093/cid/ciw804.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseHuman immunodeficiency virusDiabetes mellitusAntiretroviral therapyCumulative incidenceKidney diseaseNoncommunicable diseasesNorth American AIDS Cohort CollaborationOccurrence of DMType 2 diabetes mellitusRisk of deathDemographic subgroupsNon-black womenCohort CollaborationHIV populationImmunodeficiency virusTreatment optionsHypertensionAge 70Poisson regressionRacial disparitiesDiseaseBlack womenIncidenceCare
2015
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.
Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, Engels EA, Hessol NA, Brooks JT, Burchell AN, Gill MJ, Goedert JJ, Hogg R, Horberg MA, Kirk GD, Kitahata MM, Korthuis PT, Mathews WC, Mayor A, Modur SP, Napravnik S, Novak RM, Patel P, Rachlis AR, Sterling TR, Willig JH, Justice AC, Moore RD, Dubrow R. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Annals Of Internal Medicine 2015, 163: 507-18. PMID: 26436616, PMCID: PMC4711936, DOI: 10.7326/m14-2768.Peer-Reviewed Original ResearchConceptsAge 75 yearsNon-Hodgkin lymphomaCumulative cancer incidenceCumulative incidenceLung cancerKaposi's sarcomaCalendar trendsCohort studyHIV statusHodgkin's lymphomaCancer incidenceLiver cancerNorth American AIDS Cohort CollaborationOral cavity/pharyngeal cancerHigher cumulative incidenceMortality rate trendsCohort CollaborationAnal cancerAntiretroviral therapyPharyngeal cancerSmoking cessationColorectal cancerLifetime riskIncidence trendsUninfected adults
2011
The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis
Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J, Collaboration F. The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine 2011, 13: 89-97. PMID: 21819529, PMCID: PMC4539012, DOI: 10.1111/j.1468-1293.2011.00940.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Therapy, CombinationDrug UsersFemaleHIV InfectionsHumansMaleMiddle AgedOdds RatioProportional Hazards ModelsRisk FactorsRNA, ViralSubstance Abuse, IntravenousViral LoadYoung AdultConceptsCombination antiretroviral therapyCD4 cell countBaseline CD4 cell countDisease progressionCell countCART initiationAntiretroviral therapyHigher baseline HIV viral loadLower baseline CD4 cell countBaseline HIV viral loadSpecific causesART Cohort CollaborationLiver-related deathHIV viral loadHIV-positive individualsRisk of deathCause of deathDrug use historyCohort CollaborationCohort studyCumulative incidenceHazard ratioHIV diseaseClinical AIDSPrior diagnosis
2007
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21: 1185-1197. PMID: 17502729, PMCID: PMC3460385, DOI: 10.1097/qad.0b013e328133f285.Peer-Reviewed Original ResearchConceptsStart of HAARTCD4 cell countCell countHIV-1 RNA levelsHIV-1-infected patientsInitiation of HAARTTreatment-naive patientsDiagnosis of AIDSInjection drug useVirological responseHIV careNew AIDSCumulative incidenceParametric survival modelsClinical stageProspective studyRisk calculatorHAARTProgression rateTreatment changesPatientsDrug usePrognostic modelAIDSCells/